ICCAS leads platform development to support therapy decisions in complex blood cancers

Janssen Germany aims to improve the treatment of blood cancer through the use of artificial intelligence (AI). To this end, the research-focused pharmaceutical company supports a research project in which ICCAS and the Clinic for Hematology Cell Therapy and Hemostaseology at Leipzig University Hospital serve as the leading technology partners. Together they are pursuing the goal of developing an AI-based digital health platform for therapeutic decision support for patients with complex blood disorders. The KAIT platform will be accessible to physicians in clinics and practices and provide them with evidence-based suggestions for individualized therapy strategies. In three years the KAIT platform will be available as a reliable and practical tool to support clinical routines.

Press release (available in German)
Link to project website (German)

Back to News